<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2014.2233</article-id>
<article-id pub-id-type="publisher-id">mmr-10-02-1108</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Dual-sensitive HRE/Egr1 promoter regulates Smac overexpression and enhances radiation-induced A549 human lung adenocarcinoma cell death under hypoxia</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>CHANG-FENG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>CHEN</surname><given-names>LI-BO</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>DAN-DAN</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>YANG</surname><given-names>LEI</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>BAO-GANG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>JIN</surname><given-names>JING-PENG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>YING</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>BIN</given-names></name><xref ref-type="corresp" rid="c1-mmr-10-02-1108"/></contrib>
<aff id="af1-mmr-10-02-1108">Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China</aff></contrib-group>
<author-notes>
<corresp id="c1-mmr-10-02-1108">Correspondence to: Dr Bin Zhang, Endoscopy Center, China-Japan Union Hospital, Jilin University, 126 Xiantai Street, Changchun, Jilin 130033, P.R. China, E-mail: <email>zrlgaozl@sina.com</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>13</day>
<month>05</month>
<year>2014</year></pub-date>
<volume>10</volume>
<issue>2</issue>
<fpage>1108</fpage>
<lpage>1116</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>08</month>
<year>2013</year></date>
<date date-type="accepted">
<day>04</day>
<month>04</month>
<year>2014</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>The aim of this study was to construct an expression vector carrying the hypoxia/radiation dual-sensitive chimeric hypoxia response element (HRE)/early growth response 1 (Egr-1) promoter in order to overexpress the therapeutic second mitochondria-derived activator of caspases (Smac). Using this expression vector, the present study aimed to explore the molecular mechanism underlying radiotherapy-induced A549 human lung adenocarcinoma cell death and apoptosis under hypoxia. The plasmids, pcDNA3.1-Egr1-Smac (pE-Smac) and pcDNA3.1-HRE/Egr-1-Smac (pH/E-Smac), were constructed and transfected into A549 human lung adenocarcinoma cells using the liposome method. CoCl<sub>2</sub> was used to chemically simulate hypoxia, followed by the administration of 2 Gy X-ray irradiation. An MTT assay was performed to detect cell proliferation and an Annexin V-fluorescein isothiocyanate apoptosis detection kit was used to detect apoptosis. Quantitative polymerase chain reaction and western blot analyses were used for the detection of mRNA and protein expression, respectively. Infection with the pE-Smac and pH/E-Smac plasmids in combination with radiation and/or hypoxia was observed to enhance the expression of Smac. Furthermore, Smac overexpression was found to enhance the radiation-induced inhibition of cell proliferation and promotion of cycle arrest and apoptosis. The cytochrome <italic>c</italic>/caspase-9/caspase-3 pathway was identified to be involved in this regulation of apoptosis. Plasmid infection in combination with X-ray irradiation was found to markedly induce cell death under hypoxia. In conclusion, the hypoxia/radiation dual-sensitive chimeric HRE/Egr-1 promoter was observed to enhance the expression of the therapeutic Smac, as well as enhance the radiation-induced inhibition of cell proliferation and promotion of cycle arrest and apoptosis under hypoxia. This apoptosis was found to involve the mitochondrial pathway.</p></abstract>
<kwd-group>
<kwd>hypoxia</kwd>
<kwd>radiation</kwd>
<kwd>Smac</kwd>
<kwd>lung adenocarcinoma</kwd>
<kwd>apoptosis</kwd>
<kwd>chimeric promoter</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Radiotherapy is frequently used for the clinical treatment of lung cancer; however, its effectiveness is often impaired by radiation resistance (<xref rid="b1-mmr-10-02-1108" ref-type="bibr">1</xref>). Combining gene therapy with radiotherapy, known as gene-radiotherapy, is a novel method for cancer treatment, and has attracted particular interest (<xref rid="b2-mmr-10-02-1108" ref-type="bibr">2</xref>,<xref rid="b3-mmr-10-02-1108" ref-type="bibr">3</xref>). At present, gene-radiotherapy focuses on the radiation-inducible early growth response 1 (Egr1) promoter. This promoter contains six serum response elements, CC(A+T-rich)6GG motifs, which are sensitive to ionizing radiation (<xref rid="b4-mmr-10-02-1108" ref-type="bibr">4</xref>,<xref rid="b5-mmr-10-02-1108" ref-type="bibr">5</xref>). Numerous studies have demonstrated that, under irradiation, the Egr1 promoter is capable of regulating the overexpression of downstream genes, including TNF-&#x003B1;, IFN-&#x003B3;, endostatin and TRAIL (<xref rid="b6-mmr-10-02-1108" ref-type="bibr">6</xref>&#x02013;<xref rid="b8-mmr-10-02-1108" ref-type="bibr">8</xref>).</p>
<p>Solid tumor hypoxia occurs when the growth rate of the tumor cells exceeds that of the tumor blood vessels, resulting in insufficient tumor blood supply. Hypoxic tumor cells account for between 10 and 50&#x00025; of the cells in a solid tumor and cause radio- and chemotherapy resistance, leading to local tumor recurrence and distant metastasis (<xref rid="b9-mmr-10-02-1108" ref-type="bibr">9</xref>). Hypoxic tumor cells have unique biological features that confer radioresistance and make tumor cells more aggressive. Under hypoxia, certain protective stress proteins are upregulated in tumor cells, including hypoxia-inducible factor-1, which specifically binds to hypoxia response elements (HREs), inducing the expression of downstream genes. HRE is a hypoxic enhancer with a core sequence of 5&#x02032;-(A/G) COT (G/C) (G/C)-3&#x02032;. Previous studies have shown that placing the HRE sequence upstream of the AFP, KDR, CMV and SV40 promoters, to constitute the chimeric promoters, markedly increases their transcriptional activities under hypoxia (<xref rid="b10-mmr-10-02-1108" ref-type="bibr">10</xref>&#x02013;<xref rid="b12-mmr-10-02-1108" ref-type="bibr">12</xref>). Furthermore, placing the HRE sequence upstream of the Egr1 promoter has been found to enhance the radiation-induced overexpression of therapeutic genes in hypoxic tumor cells (<xref rid="b13-mmr-10-02-1108" ref-type="bibr">13</xref>).</p>
<p>Ionizing radiation is capable of inducing tumor cell apoptosis and cell cycle arrest. Following cell cycle arrest, ionizing radiation-induced DNA damage is repaired, with cells undergoing apoptosis if repair cannot be completed (<xref rid="b14-mmr-10-02-1108" ref-type="bibr">14</xref>). Pro-apoptotic genes can be used as targets in gene-radiotherapy. Therefore, hypoxia/radiation dual-sensitive HRE/Egr-1 promoter-mediated gene-radiotherapy may enhance hypoxic tumor cell apoptosis, increasing cell death.</p>
<p>The second mitochondria-derived activator of caspases (Smac) is located in the mitochondria and is released into the cytosol to exert its pro-apoptotic activity. Smac specifically binds to anti-apoptotic proteins, abolishing the suppression of the pro-apoptotic proteins caspase-9 and -3, which have a key role in cell apoptosis. Furthermore, Smac is capable of exerting direct pro-apoptotic effects by binding to apoptotic protease activating factor-1, cytochrome <italic>c</italic> (Cyt <italic>c</italic>) and casapse-9 (<xref rid="b15-mmr-10-02-1108" ref-type="bibr">15</xref>,<xref rid="b16-mmr-10-02-1108" ref-type="bibr">16</xref>). The overexpression of Smac has also been utilized for cancer treatment (<xref rid="b17-mmr-10-02-1108" ref-type="bibr">17</xref>,<xref rid="b18-mmr-10-02-1108" ref-type="bibr">18</xref>).</p>
<p>The aim of the present study was to investigate the molecular mechanisms underlying radiation-induced A549 cell death upon the induction of hypoxia and the overexpression of Smac. A human Smac expression vector, pcDNA3.1-HRE/Egr-1-Smac (pH/E-Smac), containing the double-sensitive HRE/Egr1 promoter, was constructed. The effect of Smac overexpression on the inhibition of cell proliferation and the promotion of cell cycle arrest and apoptosis was then assessed in A549 human lung adenocarcinoma cells subjected to hypoxia and 2 Gy X-ray irradiation.</p></sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title>Cell line</title>
<p>A549 human lung adenocarcinoma cells were purchased from Peking Union Medical College Cell Bank (Beijing, China) and were cultured in high-glucose Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (Sigma-Aldrich, St. Louis, MO, USA) containing 10&#x00025; fetal bovine serum (FBS; Gibco-BRL, Grand Island, NY, USA) and 100 U/ml penicillin and streptomycin (Gibco-BRL) at 37&#x000B0;C in 5&#x00025; CO<sub>2</sub>. A549 cells were grown to 80&#x00025; confluence in six-, 24- or 96-well culture plates prior to treatment.</p></sec>
<sec>
<title>Plasmids</title>
<p>The plasmids pcDNA3.1-Egr1-TRAIL and pcDNA3.1-HRE-Egr1-TRAIL were obtained from Dr Yanming Yang (Jilin University, Changchun, China). The pcDNA3.1-CMV-Smac plasmid was constructed as described previously (<xref rid="b19-mmr-10-02-1108" ref-type="bibr">19</xref>) and obtained from Dr Caixia Guo (Jilin University). Plasmids were digested using <italic>Hin</italic>dIII and <italic>Bam</italic>HI, and the vector backbones and <italic>Smac</italic> fragments were subsequently recycled and ligated using the T4 DNA ligase to obtain the recombinant pcDNA3.1-Egr1-Smac (pE-Smac) and pH/E-Smac plasmids. Plasmids were identified using sequencing and restriction digestion.</p></sec>
<sec>
<title>Cell transfection, hypoxia simulation and X-ray irradiation</title>
<p>A549 cells were transfected using the Lipofectamine 2000 reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer&#x02019;s instructions. Cells were cultured at 37&#x000B0;C in 5&#x00025; CO<sub>2</sub> for a further 6 h with fresh medium containing 10&#x00025; FBS. Twenty-four hours after transfection, CoCl<sub>2</sub> (Sigma-Aldrich) was added at a final concentration of 150 &#x003BC;mol/l to simulate hypoxia, as described previously (<xref rid="b20-mmr-10-02-1108" ref-type="bibr">20</xref>). X-ray irradiation was then performed 24 h subsequent to the addition of CoCl<sub>2</sub>, using the Philips Deep Therapy machine at 200 kV and 10 mA, using 0.5-mm Cu and 1-mm Al plates at 50 cm skin distance. A dose of 2 Gy was delivered at a rate of 0.287 Gy/min. The dose and dose rate were selected using the 1986 report from the United Nation Scientific Committee on the Effects of Atomic Radiation (<xref rid="b8-mmr-10-02-1108" ref-type="bibr">8</xref>,<xref rid="b21-mmr-10-02-1108" ref-type="bibr">21</xref>,<xref rid="b22-mmr-10-02-1108" ref-type="bibr">22</xref>).</p></sec>
<sec>
<title>MTT assay to detect cell proliferation</title>
<p>A549 cells were divided into six groups: Control, pE-Smac, pH/E-Smac, 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy. Briefly, A549 cells were seeded on 96-well plates at 2&#x000D7;10<sup>4</sup> cells/well, with six replicates for each treatment. After 12 h, transfection was performed. Twenty-four hours after transfection, cells were cultured in normoxic and hypoxic conditions simulated by the addition of CoCl<sub>2</sub>. After 24 h, 0 or 2 Gy X-ray radiation was administered. A total of 10 &#x003BC;l MTT (Sigma-Aldrich) was added 0, 4, 12, 24 and 48 h after irradiation, to form a final concentration of 5 mg/ml. Following 4 h of incubation, the supernatant was discarded and 100 &#x003BC;l dimethylsulfoxide (Sigma-Aldrich) was added to dissolve the crystals. The absorbance (A) value was measured at 570 nm using a microplate reader (Bio Rad, Hercules, CA, USA) (<xref rid="b8-mmr-10-02-1108" ref-type="bibr">8</xref>). The experiment was repeated three times.</p></sec>
<sec>
<title>Flow cytometry (FCM) for the analysis of the cell cycle and apoptosis</title>
<p>FCM (Becton Dickinson Co., Franklin Lakes, NJ, USA) was performed to detect cell cycle arrest and apoptosis using propidium iodide (PI; Sigma-Aldrich) and the Annexin V-fluorescein isothiocyanate (FITC) double-staining kit (Nanjing KGI Biological Technology Development Co., Ltd., Nanjing, China). Briefly, A549 cells were seeded on 24-well plates at 3&#x000D7;10<sup>5</sup> cells/well and subjected to transfection, hypoxia simulation and irradiation according to the aforementioned methods. Twenty-four hours after irradiation, cells were collected in glass centrifuge tubes and washed twice with phosphate-buffered saline (PBS). The supernatant was discarded. To detect cell cycle phase, 50 &#x003BC;l RNase A and 200 &#x003BC;l PI were added and mixed in the dark at room temperature for 20 min. To detect the cell apoptosis, cells were resuspended in 500 &#x003BC;l PBS, and 5 &#x003BC;l Annexin V-FITC and 5 &#x003BC;l PI were added and mixed in the dark at room temperature for 15 min. The cell samples were then assessed using FCM. The BD CellQuest&#x02122; (Becton Dickinson Co.) software was used to acquire and analyze the data.</p></sec>
<sec>
<title>Quantitative polymerase chain reaction (qPCR) analysis of mRNA expression</title>
<p>A549 cells were seeded on six-well plates at 5&#x000D7;10<sup>5</sup> cells/well, prior to transfection, hypoxia simulation and irradiation as described above. Cells were collected 24 h after irradiation and total RNA was extracted using TRIzol<sup>&#x000AE;</sup> Reagent (Invitrogen Life Technologies) according to the manufacturer&#x02019;s instructions. The extracted RNA was quantified by detection of the A<sub>260</sub>/A<sub>280</sub> ratio. cDNA was synthesized using a reverse transcription kit (MBI Fermentas Inc., Burlington, ON, Canada) according to the manufacturer&#x02019;s instructions (200 ng RNA, 20 &#x003BC;l reaction system). The reaction conditions were 42&#x000B0;C for 60 min, followed by 70&#x000B0;C for 2 min. The PrimeScript<sup>&#x000AE;</sup> RT-PCR kit (Takara Bio, Inc., Dalian, China) and an Mx3000P&#x02122; Real-Time PCR System (Stratagene, La Jolla, CA, USA) were used for the qPCR and the subsequent analysis of results. Primer3 software (<xref rid="b23-mmr-10-02-1108" ref-type="bibr">23</xref>) was used to design the GAPDH, Smac, Cyt c, caspase-9 and -3 primers, which were synthesized by Takara Bio, Inc. and are shown in <xref rid="tI-mmr-10-02-1108" ref-type="table">Table I</xref>. The reaction conditions were as follows: 95&#x000B0;C for 30 sec, one cycle; 95&#x000B0;C for 20 sec and 60&#x000B0;C for 20 sec, 40 cycles; 95&#x000B0;C for 1 min, one cycle; 55&#x000B0;C for 30 sec and 95&#x000B0;C for 30 sec. Relative mRNA expression was calculated as the ratio of the gene of interest mRNA/GAPDH mRNA.</p></sec>
<sec>
<title>Western blot analysis to detect protein expression</title>
<p>A549 cells were seeded on six-well plates at 1&#x000D7;10<sup>6</sup> cells/well, and subjected to transfection, hypoxia simulation and irradiation according to the aforementioned methods. Cells were collected 24 h after irradiation, and lysis buffer (10 mmol/l Tris-HCl, pH 7.4; 1 mmol/l EDTA, pH 8.0; 0.1 mol/l NaCl; 1 &#x003BC;g/ml aprotinin; 100 &#x003BC;g/ml phenylmethanesulfonyl fluoride) was used to extract the total protein. The Coomassie Brilliant Blue protein quantification kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) was used to quantify the total protein. Proteins were separated using 12&#x00025; SDS-PAGE with a sample loading of 50 &#x003BC;g/lane. Proteins were then transferred to a nitrocellulose membrane. The membrane was blocked using 5&#x00025; non-fat, dry milk for 1 h, prior to incubation with primary antibodies against &#x003B2;-actin, Smac, Cyt c, caspase-9 and -3, respectively, overnight at 4&#x000B0;C. Membranes were then washed twice using Tris-buffered saline containing 0.05&#x00025; Tween 20, prior to incubation with horseradish peroxidase-conjugated secondary antibodies at 37&#x000B0;C for 1 h (Pierce Biotechnology, Inc., Rockford, IL, USA). The enhanced chemical luminescence light system method (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used to visualize the immunoreactive bands. Images were captured for analysis.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Experimental data are presented as the mean &#x000B1; standard deviation. Results were analyzed using one-way analysis of variance with the SPSS 12.0 statistical software (SPSS, Inc., Chicago, IL, USA). A value of P&lt;0.05 was considered to indicate a statistically significant difference.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Sequencing and restriction digestion of pE-Smac and pH/E-Smac</title>
<p>The pE-Smac plasmid was digested by <italic>Sma</italic>I, <italic>Xba</italic>I and <italic>Xho</italic>I enzymes. The fragments generated were 2,292 and 3,772 bp (<italic>Sma</italic>I); 828 and 5,236 bp (<italic>Xba</italic>I) and 908 and 5,156 bp (<italic>Xho</italic>I) (<xref rid="f1-mmr-10-02-1108" ref-type="fig">Fig. 1A</xref>). The pH/E-Smac plasmid was digested using <italic>Bam</italic>HI and <italic>Sma</italic>I enzymes. The digested fragments were 1,284 and 4,926 bp (<italic>Bam</italic>HI) and 2,292 and 3,918 bp (<italic>Sma</italic>I) (<xref rid="f1-mmr-10-02-1108" ref-type="fig">Fig. 1B</xref>). All fragments were as expected, and sequencing revealed that fragment sequences were consistent with those expected (data not shown).</p></sec>
<sec>
<title>A549 cell proliferation</title>
<p>The results of the MTT assay used to assess A549 cell proliferation are shown in <xref rid="tII-mmr-10-02-1108" ref-type="table">Table II</xref>. Under normoxic conditions, no significant differences were observed in A549 cell proliferation among the control, pE-Smac and pH/E-Smac groups (P&gt;0.05). However, a significant decrease in A549 cell proliferation was observed in the 2 Gy (P&lt;0.05), pE-Smac+2 Gy and pH/E-Smac+2 Gy groups (both P&lt;0.001), compared with the control group at each time-point. Compared with normoxia, hypoxic treatment was found to significantly reduce A549 cell proliferation (P&lt;0.05 or P&lt;0.001), particularly in the pH/E-Smac+2 Gy group (P&lt;0.001).</p></sec>
<sec>
<title>A549 cell cycle phase</title>
<p><xref rid="tIII-mmr-10-02-1108" ref-type="table">Table III</xref> and <xref rid="f2-mmr-10-02-1108" ref-type="fig">Fig. 2</xref> show A549 cell cycle phase under normoxia and hypoxia, detected using FCM with PI staining. Under normoxia, in the 2 Gy, pE-Smac +2 Gy and pH/E-Smac+2 Gy groups, the proportion of cells in S phase was significantly decreased compared with the control, while the proportion of cells in G<sub>2</sub>/M phase was significantly increased compared with the control (P&lt;0.05). No significant differences were observed in the other treatment groups under normoxia. Under hypoxia, in the pH/E-Smac, 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups, the proportion of cells in the G<sub>0</sub>/G<sub>1</sub> and G<sub>2</sub>/M phases was observed to be significantly increased compared with the control, while the proportion in S phase was found to be significantly reduced (P&lt;0.05 or P&lt;0.001). With the exception of the G<sub>2</sub>/M phase in the control and pE-Smac groups, the changes in the percentage of cells in G<sub>0</sub>/G<sub>1</sub>, S and G<sub>2</sub>/M phases under hypoxia were significantly greater than those under normoxia (P&lt;0.05 or P&lt;0.001). These findings suggest that 2 Gy X-ray irradiation can induce G<sub>2</sub>/M-phase arrest and that hypoxia induces G<sub>0</sub>/G<sub>1</sub> arrest. The greatest cell cycle arrest was achieved in the pH/E-Smac+2 Gy group under hypoxia.</p></sec>
<sec>
<title>A549 cell apoptosis</title>
<p><xref rid="tIV-mmr-10-02-1108" ref-type="table">Table IV</xref> and <xref rid="f3-mmr-10-02-1108" ref-type="fig">Fig. 3</xref> show the results of the FCM used to detect A549 cell apoptosis under normoxia and hypoxia. Under normoxia, the percentage of apoptotic A549 cells in the 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups was observed to be significantly increased compared with that in the control group (P&lt;0.05 or P&lt;0.01), particularly in the pE-Smac+2 Gy and pH/E-Smac+2 Gy groups. No significant difference was observed between the pE-Smac+2 Gy and pH/E-Smac+2 Gy groups. Under hypoxia, the percentage of apoptotic A549 cells in the pH/E-Smac, 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups was increased significantly compared with that in the control group (P&lt;0.05 or P&lt;0.01), particularly in the pH/E-Smac+2 Gy group. Furthermore, the percentage of apoptotic cells in each hypoxic group was found to be increased significantly compared with each normoxic group (P&lt;0.05 or P&lt;0.01).</p></sec>
<sec>
<title>Smac, Cyt c and caspase-9 and -3 mRNA expression in A549 cells</title>
<p>qPCR analysis was performed to detect Smac, Cyt <italic>c</italic>, and caspase-9 and -3 mRNA expression. The relative mRNA levels were calculated as the ratio of experimental/control mRNA expression, as shown in <xref rid="tV-mmr-10-02-1108" ref-type="table">Table V</xref>. With the exception of Cyt <italic>c</italic> expression in the 2 Gy group, under normoxia Smac, Cyt <italic>c</italic>, and caspase-9 and -3 mRNA levels in the 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups were significantly increased compared with those in the control group (P&lt;0.05 or P&lt;0.01), with no significant difference observed in the mRNA expression between the pE-Smac+2 Gy and pH/E-Smac+2 Gy groups. With the exception of Cyt <italic>c</italic> and caspase-3 in the pH/E-Smac group, the mRNA levels of Smac, Cyt <italic>c</italic>, and caspase-9 and -3 in the pH/E-Smac, 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups under hypoxia were found to be significantly increased compared with those in the control group (P&lt;0.05 or P&lt;0.001), particularly in the pH/E-Smac+2 Gy group. Overall, with the exception of Cyt <italic>c</italic> in the control, pE-Smac and pE-Smac+2 Gy groups, hypoxia was found to significantly increase Smac, Cyt <italic>c</italic>, caspase-9 and -3 mRNA levels compared with normoxia (P&lt;0.05 or P&lt;0.001).</p></sec>
<sec>
<title>Smac, Cyt c, casapase-9 and -3 protein expression in A549 cells</title>
<p>As shown in <xref rid="f4-mmr-10-02-1108" ref-type="fig">Fig. 4</xref>, western blot analysis was used to detect Smac, Cyt <italic>c</italic>, and caspase-9 and -3 protein expression. Under normoxia, the expression of the housekeeping protein &#x003B2;-actin (molecular weight, 42 kDa) was consistent in each group. The protein expression of Smac (25 kDa) and Cyt c (12 kDa) was observed to increase in the 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups, while that of the caspase-9 and -3 precursors (42 kDa and 27 kDa, respectively) were consistent among all six groups. Expression of the activated caspase-9 protein (35 kDa) was observed to increase in the 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups, and that of the activated caspase-3 protein (21 kDa) was found to increase in the pE-Smac+2 Gy and pH/E-Smac+2 Gy groups.</p>
<p>Under hypoxia, expression of the housekeeping protein &#x003B2;-actin was consistent in each group. However, the protein expression of Smac and Cyt <italic>c</italic> was observed to increase in the pH/E-Smac, 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups, with the highest expression observed in the pH/E-Smac+2 Gy group. The expression of the precursor and activated caspase-9 proteins was found to increase under hypoxia, particularly in the pE-Smac+2 Gy and pH/E-Smac+2 Gy groups. No difference was observed in the expression of the caspase-3 precursor protein under hypoxia; however, the expression of the activated protein was found to increase in the 2 Gy, pE-Smac+2 Gy and pH/E-Smac+2 Gy groups, particularly in the pH/E-Smac+2 Gy group. When compared with normoxia, hypoxic treatment was found to increase the expression of the Smac, Cyt c and caspase-9 and -3 precursor and activated proteins.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Cells in solid tumors cause a hypoxic microenvironment, which results in radiation resistance (<xref rid="b24-mmr-10-02-1108" ref-type="bibr">24</xref>). Based on the hypoxia-inducible nature of the HRE promoter (<xref rid="b10-mmr-10-02-1108" ref-type="bibr">10</xref>&#x02013;<xref rid="b12-mmr-10-02-1108" ref-type="bibr">12</xref>), the present study aimed to use the HRE promoter in lung cancer gene therapy to promote the downstream expression of the therapeutic Smac and increase the tumor cell death. Furthermore, the radiation-inducible Egr-1 promoter, which is activated and regulated by ionizing radiation in a temporal and spatial dose-dependent manner (<xref rid="b6-mmr-10-02-1108" ref-type="bibr">6</xref>,<xref rid="b8-mmr-10-02-1108" ref-type="bibr">8</xref>,<xref rid="b25-mmr-10-02-1108" ref-type="bibr">25</xref>), was used to enhance the expression of the <italic>Smac</italic> gene. The present study combined the HRE and Egr-1 promoters, forming a dual-sensitive chimeric HRE/Egr-1 promoter to induce the expression of the pro-apoptotic <italic>Smac</italic> gene in A549 human lung adenocarcinoma cells subjected to hypoxia and X-ray irradiation. The results showed that 2 Gy X-ray radiation alone was capable of inducing the Egr-1 promoter to enhance the expression of Smac. The HRE promoter is inactive under normoxia. Under hypoxia, 2 Gy X-ray radiation was observed to markedly enhance Smac expression in A549 cells. Therefore, the radiation-induced Egr-1 promoter and the hypoxia-induced HRE promoter may synergize to improve the efficacy of radiotherapy.</p>
<p>The overexpression of Smac has been reported to promote tumor cell apoptosis through the mitochondrial pathway and enhance the sensitivity of tumor cells to radio- and chemotherapy (<xref rid="b26-mmr-10-02-1108" ref-type="bibr">26</xref>&#x02013;<xref rid="b32-mmr-10-02-1108" ref-type="bibr">32</xref>). The present study found that the overexpression of Smac in A549 cells under normoxia enhanced X-ray radiation-induced G<sub>2</sub>/M arrest and apoptosis, and increased the protein and mRNA expression of Cyt <italic>c</italic>, and caspase-9 and -3. These findings indicate that Smac overexpression is capable of inducing A549 cell apoptosis by activating caspase-9 and -3 and increasing Cyt <italic>c</italic>, suggesting that the Cyt <italic>c</italic>/caspase-9/caspase-3 pathway is involved in the regulation of apoptosis.</p>
<p>In accordance with a study by Zeng <italic>et al</italic> (<xref rid="b33-mmr-10-02-1108" ref-type="bibr">33</xref>), CoCl<sub>2</sub>-simulated hypoxia in the present study was observed to induce G<sub>0</sub>/G<sub>1</sub> arrest. G<sub>0</sub>/G<sub>1</sub> arrest renders cells sensitive to radiation, which enhances the efficacy of radiotherapy (<xref rid="b34-mmr-10-02-1108" ref-type="bibr">34</xref>). Hypoxia-induced G<sub>0</sub>/G<sub>1</sub> arrest also enhances radiation-induced apoptosis without radiation resistance. In the present study, the HRE/Egr-1 promoter was found to mediate the overexpression of Smac, leading to enhanced G<sub>2</sub>/M arrest in A549 cells. G<sub>2</sub>/M arrest also renders cells sensitive to radiation. In this study, compared with cells under normoxia, hypoxic cells were observed to exhibit enhanced apoptosis, G<sub>2</sub>/M arrest and expression of Cyt <italic>c</italic>, as well as caspase-9 and -3. These findings indicate that the constructed hypoxia/radiation dual-sensitive chimeric HRE/Egr-1 promoter has a role in gene therapy under hypoxia.</p>
<p>In conclusion, the hypoxia/radiation dual-sensitive HRE/Egr-1 promoter-mediated Smac overexpression vector was successfully constructed in the present study. Following transfection of A549 human lung adenocarcinoma cells, radiation and hypoxia were observed to induce the overexpression of Smac, leading to proliferation inhibition, enhanced apoptosis and G<sub>2</sub>/M-phase arrest. Furthermore, cell apoptosis was found to involve the mitochondrial Cyt <italic>c</italic>/caspase-9/caspase-3 pathway. HRE/Egr-1 promoter-mediated gene-radiotherapy achieved enhanced efficacy and synergized radiotherapy and gene therapy, providing an experimental basis for gene-radiotherapy in lung cancer.</p></sec></body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-mmr-10-02-1108"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>DL</given-names></name><name><surname>Sham</surname><given-names>JS</given-names></name><name><surname>Leung</surname><given-names>LH</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Ng</surname><given-names>WM</given-names></name><name><surname>Kwong</surname><given-names>PW</given-names></name><name><surname>Lui</surname><given-names>WM</given-names></name><name><surname>Yau</surname><given-names>CC</given-names></name><name><surname>Wu</surname><given-names>PM</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Au</surname><given-names>G</given-names></name></person-group><article-title>Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>64</volume><fpage>374</fpage><lpage>381</lpage><year>2006</year></element-citation></ref>
<ref id="b2-mmr-10-02-1108"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>AQ</given-names></name><name><surname>Song</surname><given-names>XR</given-names></name><name><surname>Yu</surname><given-names>JM</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>XW</given-names></name></person-group><article-title>Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice</article-title><source>World J Gastroenterol</source><volume>11</volume><fpage>4439</fpage><lpage>4442</lpage><year>2005</year></element-citation></ref>
<ref id="b3-mmr-10-02-1108"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harari</surname><given-names>PM</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name></person-group><article-title>Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>49</volume><fpage>427</fpage><lpage>433</lpage><year>2001</year></element-citation></ref>
<ref id="b4-mmr-10-02-1108"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><name><surname>Kufe</surname><given-names>D</given-names></name></person-group><article-title>Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers</article-title><source>Cancer Gene Ther</source><volume>16</volume><fpage>609</fpage><lpage>619</lpage><year>2009</year></element-citation></ref>
<ref id="b5-mmr-10-02-1108"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kufe</surname><given-names>D</given-names></name><name><surname>Weichselbaum</surname><given-names>R</given-names></name></person-group><article-title>Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology</article-title><source>Cancer Biol Ther</source><volume>2</volume><fpage>326</fpage><lpage>329</lpage><year>2003</year></element-citation></ref>
<ref id="b6-mmr-10-02-1108"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LL</given-names></name><name><surname>Smith</surname><given-names>MJ</given-names></name><name><surname>Sun</surname><given-names>BS</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Redmond</surname><given-names>HP</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name></person-group><article-title>Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model</article-title><source>Ann Surg Oncol</source><volume>16</volume><fpage>1403</fpage><lpage>1411</lpage><year>2009</year></element-citation></ref>
<ref id="b7-mmr-10-02-1108"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name></person-group><article-title>Anti-tumor effect of pEgr-interferon-gamma-endostatin gene-radiotherapy in mice bearing Lewis lung carcinoma and its mechanism</article-title><source>Chin Med J (Engl)</source><volume>118</volume><fpage>296</fpage><lpage>301</lpage><year>2005</year></element-citation></ref>
<ref id="b8-mmr-10-02-1108"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>S</given-names></name></person-group><article-title>Enhanced effects of TRAIL-endostatin-based double-gene-radiotherapy on suppressing growth, promoting apoptosis and inducing cell cycle arrest in vascular endothelial cells</article-title><source>J Huazhong Univ Sci Technolog Med Sci</source><volume>32</volume><fpage>167</fpage><lpage>172</lpage><year>2012</year></element-citation></ref>
<ref id="b9-mmr-10-02-1108"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toma-Da&#x0015F;u</surname><given-names>I</given-names></name><name><surname>Da&#x0015F;u</surname><given-names>A</given-names></name><name><surname>Karlsson</surname><given-names>M</given-names></name></person-group><article-title>The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumor response to radiation</article-title><source>Phys Med Biol</source><volume>49</volume><fpage>4463</fpage><lpage>4475</lpage><year>2004</year></element-citation></ref>
<ref id="b10-mmr-10-02-1108"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>CN</given-names></name><name><surname>Ponka</surname><given-names>P</given-names></name></person-group><article-title>Identification of a hypoxia response element in the transferrin receptor gene</article-title><source>J Biol Chem</source><volume>274</volume><fpage>24147</fpage><lpage>24152</lpage><year>1999</year></element-citation></ref>
<ref id="b11-mmr-10-02-1108"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okino</surname><given-names>ST</given-names></name><name><surname>Chichester</surname><given-names>CH</given-names></name><name><surname>Whitlock</surname><given-names>JP</given-names><suffix>Jr</suffix></name></person-group><article-title>Hypoxia-inducible mammalian gene expression analyzed in vivo at a TATA-driven promoter and at an initiator-driven promoter</article-title><source>J Biol Chem</source><volume>273</volume><fpage>23837</fpage><lpage>23843</lpage><year>1998</year></element-citation></ref>
<ref id="b12-mmr-10-02-1108"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>OJ</given-names></name><name><surname>Kim</surname><given-names>PH</given-names></name><name><surname>Huyn</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Yun</surname><given-names>CO</given-names></name></person-group><article-title>A hypoxia-and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas</article-title><source>Clin Cancer Res</source><volume>16</volume><fpage>6071</fpage><lpage>6082</lpage><year>2010</year></element-citation></ref>
<ref id="b13-mmr-10-02-1108"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leskov</surname><given-names>KS</given-names></name><name><surname>Criswell</surname><given-names>T</given-names></name><name><surname>Antonio</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>CR</given-names></name><name><surname>Kinsella</surname><given-names>TJ</given-names></name><name><surname>Boothman</surname><given-names>DA</given-names></name></person-group><article-title>When X-ray-inducible proteins meet DNA double strand break repair</article-title><source>Semin Radiat Oncol</source><volume>11</volume><fpage>352</fpage><lpage>372</lpage><year>2001</year></element-citation></ref>
<ref id="b14-mmr-10-02-1108"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WD</given-names></name><name><surname>Chen</surname><given-names>ZT</given-names></name><name><surname>Li</surname><given-names>DZ</given-names></name><name><surname>Duan</surname><given-names>YZ</given-names></name><name><surname>Wang</surname><given-names>ZX</given-names></name><name><surname>Cao</surname><given-names>ZH</given-names></name></person-group><article-title>HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter</article-title><source>Ai Zheng</source><volume>23</volume><fpage>788</fpage><lpage>793</lpage><year>2004</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b15-mmr-10-02-1108"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Chai</surname><given-names>J</given-names></name><name><surname>Suber</surname><given-names>TL</given-names></name><name><surname>Wu</surname><given-names>JW</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Structural basis of IAP recognition by Smac/DIABLO</article-title><source>Nature</source><volume>408</volume><fpage>1008</fpage><lpage>1012</lpage><year>2000</year></element-citation></ref>
<ref id="b16-mmr-10-02-1108"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000FC;hlethaler-Mottet</surname><given-names>A</given-names></name><name><surname>Bourloud</surname><given-names>KB</given-names></name><name><surname>Auderset</surname><given-names>K</given-names></name><name><surname>Joseph</surname><given-names>JM</given-names></name><name><surname>Gross</surname><given-names>N</given-names></name></person-group><article-title>Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP</article-title><source>Oncogene</source><volume>23</volume><fpage>5415</fpage><lpage>5425</lpage><year>2004</year></element-citation></ref>
<ref id="b17-mmr-10-02-1108"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeish</surname><given-names>IA</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>McKay</surname><given-names>T</given-names></name><name><surname>Tenev</surname><given-names>T</given-names></name><name><surname>Marani</surname><given-names>M</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name></person-group><article-title>Expression of Smac/DABLO in ovarian carcinoma cells induces apoptosis via a caspase-9 mediated pathway</article-title><source>Exp Cell Res</source><volume>286</volume><fpage>186</fpage><lpage>198</lpage><year>2008</year></element-citation></ref>
<ref id="b18-mmr-10-02-1108"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>LJ</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>ZW</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name></person-group><article-title>Overexpression of Smac gene enhanced chemotherapeutic sensitivity of esophageal cancer cell line Eca109 to cisplatin</article-title><source>Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</source><volume>28</volume><fpage>344</fpage><lpage>346</lpage><year>2012</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b19-mmr-10-02-1108"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Enhancement of antiproliferative and proapoptotic effects of cadmium chloride combined with hSmac in hepatocellular carcinoma cells</article-title><source>Chemotherapy</source><volume>57</volume><fpage>27</fpage><lpage>34</lpage><year>2011</year></element-citation></ref>
<ref id="b20-mmr-10-02-1108"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xiu</surname><given-names>R</given-names></name></person-group><article-title>Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl<sub>2</sub> in cultured cancer cells</article-title><source>J Pineal Res</source><volume>44</volume><fpage>121</fpage><lpage>126</lpage><year>2008</year></element-citation></ref>
<ref id="b21-mmr-10-02-1108"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Gong</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name></person-group><article-title>Effect of low-level radiation on the death of male germ cells</article-title><source>Radiat Res</source><volume>165</volume><fpage>379</fpage><lpage>389</lpage><year>2006</year></element-citation></ref>
<ref id="b22-mmr-10-02-1108"><label>22</label><element-citation publication-type="confproc"><article-title>United Nations Scientific Committee on the Effects of Atomic Radiation: 1986 Report to the General Assembly, with annexes</article-title><conf-name>General Assembly Official Records: Forty-first session, Supplement No. 16 (A/41/16)</conf-name><publisher-name>United Nations</publisher-name><publisher-loc>New York, NY</publisher-loc><year>1986</year></element-citation></ref>
<ref id="b23-mmr-10-02-1108"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koressaar</surname><given-names>T</given-names></name><name><surname>Remm</surname><given-names>M</given-names></name></person-group><article-title>Enhancements and modifications of primer design program Primer3</article-title><source>Bioinformatics</source><volume>23</volume><fpage>1289</fpage><lpage>1291</lpage><year>2007</year></element-citation></ref>
<ref id="b24-mmr-10-02-1108"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>H</given-names></name></person-group><article-title>How can we overcome tumor hypoxia in radiation therapy?</article-title><source>J Radiat Res</source><volume>52</volume><fpage>545</fpage><lpage>556</lpage><year>2011</year></element-citation></ref>
<ref id="b25-mmr-10-02-1108"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>FL</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>WJ</given-names></name></person-group><article-title>Current status of tumor radiogenic therapy</article-title><source>World J Gastroenterol</source><volume>11</volume><fpage>3014</fpage><lpage>3019</lpage><year>2005</year></element-citation></ref>
<ref id="b26-mmr-10-02-1108"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizutani</surname><given-names>Y</given-names></name><name><surname>Nakanishi</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>YN</given-names></name><name><surname>Matsubara</surname><given-names>H</given-names></name><name><surname>Mikami</surname><given-names>K</given-names></name><name><surname>Okihara</surname><given-names>K</given-names></name><name><surname>Kawauchi</surname><given-names>A</given-names></name><name><surname>Bonavida</surname><given-names>B</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name></person-group><article-title>Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance</article-title><source>J Clin Oncol</source><volume>23</volume><fpage>448</fpage><lpage>454</lpage><year>2005</year></element-citation></ref>
<ref id="b27-mmr-10-02-1108"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pluta</surname><given-names>P</given-names></name><name><surname>Cebula-Obrzut</surname><given-names>B</given-names></name><name><surname>Ehemann</surname><given-names>V</given-names></name><etal/></person-group><article-title>Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients</article-title><source>Neoplasma</source><volume>58</volume><fpage>430</fpage><lpage>435</lpage><year>2011</year></element-citation></ref>
<ref id="b28-mmr-10-02-1108"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Debatin</surname><given-names>KM</given-names></name></person-group><article-title>Smac agonists sensitize for Apo-2L/TRAIL or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo</article-title><source>Nat Med</source><volume>8</volume><fpage>808</fpage><lpage>815</lpage><year>2002</year></element-citation></ref>
<ref id="b29-mmr-10-02-1108"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Vucic</surname><given-names>D</given-names></name></person-group><article-title>Targeting IAP proteins for therapeutic intervention in cancer</article-title><source>Nat Rev Drug Discov</source><volume>11</volume><fpage>109</fpage><lpage>124</lpage><year>2012</year></element-citation></ref>
<ref id="b30-mmr-10-02-1108"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bras</surname><given-names>M</given-names></name><name><surname>Rouy</surname><given-names>I</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name></person-group><article-title>The modulation of inter-organelle cross-talk to control apoptosis</article-title><source>Med Chem</source><volume>2</volume><fpage>1</fpage><lpage>12</lpage><year>2006</year></element-citation></ref>
<ref id="b31-mmr-10-02-1108"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>L</given-names></name><name><surname>Sebasti&#x000E0;</surname><given-names>J</given-names></name><name><surname>Tuffy</surname><given-names>LP</given-names></name><name><surname>Spring</surname><given-names>A</given-names></name><name><surname>Lichawska</surname><given-names>A</given-names></name><name><surname>Devocelle</surname><given-names>M</given-names></name><name><surname>Prehn</surname><given-names>JH</given-names></name><name><surname>Rehm</surname><given-names>M</given-names></name></person-group><article-title>XIAP impairs Smac release from the mitochondria during apoptosis</article-title><source>Cell Death Dis</source><volume>1</volume><fpage>e49</fpage><year>2010</year></element-citation></ref>
<ref id="b32-mmr-10-02-1108"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>LL</given-names></name><name><surname>Zhou</surname><given-names>LY</given-names></name><name><surname>Luo</surname><given-names>KQ</given-names></name><name><surname>Chang</surname><given-names>DC</given-names></name></person-group><article-title>Smac/DIABLO and cytochrome <italic>c</italic> are released from mitochondria through a similar mechanism during UV-induced apoptosis</article-title><source>Apoptosis</source><volume>10</volume><fpage>289</fpage><lpage>99</lpage><year>2005</year></element-citation></ref>
<ref id="b33-mmr-10-02-1108"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>HL</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Qin</surname><given-names>YL</given-names></name><name><surname>Bu</surname><given-names>QQ</given-names></name><name><surname>Han</surname><given-names>XA</given-names></name><name><surname>Jia</surname><given-names>HT</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name></person-group><article-title>Hypoxia-mimetic agents inhibit proliferation and alter the morphology of human umbilical cord-derived mesenchymal stem cells</article-title><source>BMC Cell Biol</source><volume>12</volume><fpage>32</fpage><year>2011</year></element-citation></ref>
<ref id="b34-mmr-10-02-1108"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Harari</surname><given-names>PM</given-names></name></person-group><article-title>Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis</article-title><source>Clin Cancer Res</source><volume>6</volume><fpage>2166</fpage><lpage>2174</lpage><year>2000</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-mmr-10-02-1108" position="float">
<label>Figure 1</label>
<caption>
<p>Identification of (A) pE-Smac and (B) pH/E-Smac using restriction digestion. pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac.</p></caption>
<graphic xlink:href="MMR-10-02-1108-g00.gif"/></fig>
<fig id="f2-mmr-10-02-1108" position="float">
<label>Figure 2</label>
<caption>
<p>Percentage of A549 cells in each cycle phase, as determined by flow cytometry. pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac.</p></caption>
<graphic xlink:href="MMR-10-02-1108-g01.gif"/></fig>
<fig id="f3-mmr-10-02-1108" position="float">
<label>Figure 3</label>
<caption>
<p>Percentage of apoptotic A549 cells, as determined by flow cytometry. FITC, fluorescein isothiocyanate; pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac.</p></caption>
<graphic xlink:href="MMR-10-02-1108-g02.gif"/></fig>
<fig id="f4-mmr-10-02-1108" position="float">
<label>Figure 4</label>
<caption>
<p>Protein expression of Smac, Cyt c, caspase-9 and -3 in A549 cells, as determined using western blot analysis. Lane 1, control; lane 2, pE-Smac; lane 3, pH/E-Smac; lane 4, 2 Gy; lane 5, pE-Smac+2 Gy; lane 6, pH/E-Smac+2 Gy. pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac; Cyt <italic>c</italic>, cytochrome <italic>c</italic>; Smac, second mitochondria-derived activator of caspases.</p></caption>
<graphic xlink:href="MMR-10-02-1108-g03.gif"/></fig>
<table-wrap id="tI-mmr-10-02-1108" position="float">
<label>Table I</label>
<caption>
<p>Primer sequences.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left">Gene</th>
<th valign="bottom" align="center">Sequence</th></tr></thead>
<tbody>
<tr>
<td colspan="2" valign="top" align="left"><italic>GAPDH</italic></td></tr>
<tr>
<td valign="top" align="left">&#x02003;Sense</td>
<td valign="top" align="left">5&#x02032;-ACCACAGTCCATGCCATCAC-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Antisense</td>
<td valign="top" align="left">5&#x02032;-TCCACCACCCTGTTGCTGTA-3&#x02032;</td></tr>
<tr>
<td colspan="2" valign="top" align="left">Smac</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Sense</td>
<td valign="top" align="left">5&#x02032;-CTGTCGCGCAGCGTAACTTC-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Antisense</td>
<td valign="top" align="left">5&#x02032;-GGTTACTCCAAAGCCAATCGTCA-3&#x02032;</td></tr>
<tr>
<td colspan="2" valign="top" align="left">Cyt <italic>c</italic></td></tr>
<tr>
<td valign="top" align="left">&#x02003;Sense</td>
<td valign="top" align="left">5&#x02032;-GGGCGAGAGCTATGTAATGCAAG-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Antisense</td>
<td valign="top" align="left">5&#x02032;-TACAGCCAAAGCAGCAGCTCA-3&#x02032;</td></tr>
<tr>
<td colspan="2" valign="top" align="left">Caspase-9</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Sense</td>
<td valign="top" align="left">5&#x02032;-GGACATCCAGCGGGCAGG-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Antisense</td>
<td valign="top" align="left">5&#x02032;-TCTAAGCAGGAGATGAACAAAGG-3&#x02032;</td></tr>
<tr>
<td colspan="2" valign="top" align="left">Caspase-3</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Sense</td>
<td valign="top" align="left">5&#x02032;-TTCAGGCCTGCCGTGGTACA-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Antisense</td>
<td valign="top" align="left">5&#x02032;-CCAAGAATAATAACCAGGTGCT-3&#x02032;</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-mmr-10-02-1108">
<p>Smac, second mitochondria-derived activator of caspases; Cyt <italic>c</italic>, cytochrome <italic>c</italic>.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tII-mmr-10-02-1108" position="float">
<label>Table II</label>
<caption>
<p>Absorbance value of A549 cells under normoxia and hypoxia.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left"/>
<th colspan="5" valign="bottom" align="center">Time (h)</th></tr>
<tr>
<th valign="bottom" align="left"/>
<th colspan="5" valign="bottom" align="left">
<hr/></th></tr>
<tr>
<th valign="bottom" align="left">Groups</th>
<th valign="bottom" align="center">0</th>
<th valign="bottom" align="center">4</th>
<th valign="bottom" align="center">12</th>
<th valign="bottom" align="center">24</th>
<th valign="bottom" align="center">48</th></tr></thead>
<tbody>
<tr>
<td colspan="6" valign="top" align="left">Normoxia</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Control</td>
<td valign="top" align="left">0.416&#x000B1;0.002</td>
<td valign="top" align="left">0.423&#x000B1;0.008</td>
<td valign="top" align="left">0.489&#x000B1;0.023</td>
<td valign="top" align="left">0.665&#x000B1;0.058</td>
<td valign="top" align="left">0.787&#x000B1;0.035</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac</td>
<td valign="top" align="left">0.424&#x000B1;0.008</td>
<td valign="top" align="left">0.415&#x000B1;0.011</td>
<td valign="top" align="left">0.490&#x000B1;0.021</td>
<td valign="top" align="left">0.663&#x000B1;0.017</td>
<td valign="top" align="left">0.758&#x000B1;0.060</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac</td>
<td valign="top" align="left">0.414&#x000B1;0.016</td>
<td valign="top" align="left">0.414&#x000B1;0.005</td>
<td valign="top" align="left">0.452&#x000B1;0.027</td>
<td valign="top" align="left">0.628&#x000B1;0.056</td>
<td valign="top" align="left">0.775&#x000B1;0.037</td></tr>
<tr>
<td valign="top" align="left">&#x02003;2 Gy</td>
<td valign="top" align="left">0.432&#x000B1;0.010<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="left">0.410&#x000B1;0.003<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="left">0.421&#x000B1;0.003<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="left">0.431&#x000B1;0.004<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="left">0.469&#x000B1;0.009<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac+2 Gy</td>
<td valign="top" align="left">0.435&#x000B1;0.011<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="left">0.385&#x000B1;0.006<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="left">0.361&#x000B1;0.012<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="left">0.367&#x000B1;0.008<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="left">0.381&#x000B1;0.005<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac+2 Gy</td>
<td valign="top" align="left">0.442&#x000B1;0.013<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="left">0.381&#x000B1;0.009<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="left">0.361&#x000B1;0.009<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="left">0.368&#x000B1;0.014<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="left">0.378&#x000B1;0.021<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td></tr>
<tr>
<td colspan="6" valign="top" align="left">Hypoxia</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Control</td>
<td valign="top" align="left">0.383&#x000B1;0.050</td>
<td valign="top" align="left">0.419&#x000B1;0.018</td>
<td valign="top" align="left">0.387&#x000B1;0.009<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.460&#x000B1;0.041<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.495&#x000B1;0.034<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac</td>
<td valign="top" align="left">0.402&#x000B1;0.011<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.412&#x000B1;0.010</td>
<td valign="top" align="left">0.393&#x000B1;0.005<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.485&#x000B1;0.023<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="left">0.459&#x000B1;0.028<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac</td>
<td valign="top" align="left">0.347&#x000B1;0.008<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="left">0.339&#x000B1;0.006<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="left">0.385&#x000B1;0.007<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.424&#x000B1;0.008<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.422&#x000B1;0.009<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;2 Gy</td>
<td valign="top" align="left">0.408&#x000B1;0.006<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.399&#x000B1;0.007</td>
<td valign="top" align="left">0.353&#x000B1;0.015<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.397&#x000B1;0.010<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.410&#x000B1;0.009<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac+2 Gy</td>
<td valign="top" align="left">0.413&#x000B1;0.009<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="left">0.394&#x000B1;0.006<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="left">0.323&#x000B1;0.013<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.343&#x000B1;0.006<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.350&#x000B1;0.008<xref rid="tfn3-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac+2 Gy</td>
<td valign="top" align="left">0.339&#x000B1;0.004<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.329&#x000B1;0.020<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.290&#x000B1;0.016<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="left">0.254&#x000B1;0.032<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn5-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">0.153&#x000B1;0.026<xref rid="tfn4-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn6-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr></tbody></table>
<table-wrap-foot><fn id="tfn2-mmr-10-02-1108">
<p>Data are presented as the mean &#x000B1; standard deviation, n=6.</p></fn><fn id="tfn3-mmr-10-02-1108">
<label>a</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn4-mmr-10-02-1108">
<label>b</label>
<p>P&lt;0.001 versus control group;</p></fn><fn id="tfn5-mmr-10-02-1108">
<label>c</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn6-mmr-10-02-1108">
<label>d</label>
<p>P&lt;0.001 versus normoxia.</p></fn><fn id="tfn7-mmr-10-02-1108">
<p>pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tIII-mmr-10-02-1108" position="float">
<label>Table III</label>
<caption>
<p>Percentage of A549 cells in each cell cycle phase under normoxia and hypoxia.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left"/>
<th colspan="3" valign="bottom" align="center">Cell percentage (&#x00025;)</th></tr>
<tr>
<th valign="bottom" align="left"/>
<th colspan="3" valign="bottom" align="left">
<hr/></th></tr>
<tr>
<th valign="bottom" align="left">Groups</th>
<th valign="bottom" align="center">G<sub>0</sub>/G<sub>1</sub></th>
<th valign="bottom" align="center">S</th>
<th valign="bottom" align="center">G<sub>2</sub>/M</th></tr></thead>
<tbody>
<tr>
<td colspan="4" valign="top" align="left">Normoxia</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Control</td>
<td valign="top" align="left">54.17&#x000B1;1.59</td>
<td valign="top" align="center">42.69&#x000B1;4.55</td>
<td valign="top" align="center">3.13&#x000B1;1.18</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac</td>
<td valign="top" align="left">53.78&#x000B1;0.69</td>
<td valign="top" align="center">42.77&#x000B1;0.53</td>
<td valign="top" align="center">3.45&#x000B1;0.49</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac</td>
<td valign="top" align="left">54.04&#x000B1;2.34</td>
<td valign="top" align="center">39.44&#x000B1;1.99</td>
<td valign="top" align="center">2.86&#x000B1;0.68</td></tr>
<tr>
<td valign="top" align="left">&#x02003;2 Gy</td>
<td valign="top" align="left">61.55&#x000B1;1.42</td>
<td valign="top" align="center">31.92&#x000B1;1.23<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">6.53&#x000B1;0.21<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac+2 Gy</td>
<td valign="top" align="left">61.85&#x000B1;2.33</td>
<td valign="top" align="center">31.95&#x000B1;1.51<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">6.23&#x000B1;0.89<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac+2 Gy</td>
<td valign="top" align="left">60.89&#x000B1;2.09</td>
<td valign="top" align="center">32.91&#x000B1;1.86<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">6.20&#x000B1;0.26<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref></td></tr>
<tr>
<td colspan="4" valign="top" align="left">Hypoxia</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Control</td>
<td valign="top" align="left">65.47&#x000B1;0.62<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">31.40&#x000B1;0.60<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">3.13&#x000B1;0.21</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac</td>
<td valign="top" align="left">65.55&#x000B1;1.48<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">30.91&#x000B1;1.66<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">3.54&#x000B1;0.92</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac</td>
<td valign="top" align="left">70.72&#x000B1;0.86<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">11.79&#x000B1;1.33<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref>,<xref rid="tfn10-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">17.49&#x000B1;1.21<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;2 Gy</td>
<td valign="top" align="left">71.51&#x000B1;0.89<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">10.82&#x000B1;1.26<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref>,<xref rid="tfn10-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">17.67&#x000B1;0.53<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref>,<xref rid="tfn10-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac+2 Gy</td>
<td valign="top" align="left">71.74&#x000B1;1.20<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">6.85&#x000B1;1.29<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref>,<xref rid="tfn10-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">21.41&#x000B1;0.62<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref>,<xref rid="tfn10-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac+2 Gy</td>
<td valign="top" align="left">70.74&#x000B1;0.27<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">7.12&#x000B1;1.54<xref rid="tfn12-mmr-10-02-1108" ref-type="table-fn">c</xref>,<xref rid="tfn10-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">22.15&#x000B1;1.29<xref rid="tfn9-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn11-mmr-10-02-1108" ref-type="table-fn">b</xref></td></tr></tbody></table>
<table-wrap-foot><fn id="tfn8-mmr-10-02-1108">
<p>Data are presented as the mean &#x000B1; standard deviation, n=3.</p></fn><fn id="tfn9-mmr-10-02-1108">
<label>a</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn10-mmr-10-02-1108">
<label>d</label>
<p>P&lt;0.01 versus control group;</p></fn><fn id="tfn11-mmr-10-02-1108">
<label>b</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn12-mmr-10-02-1108">
<label>c</label>
<p>P&lt;0.001 versus normoxia.</p></fn><fn id="tfn13-mmr-10-02-1108">
<p>pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tIV-mmr-10-02-1108" position="float">
<label>Table IV</label>
<caption>
<p>Percentage of apoptotic A549 cells under normoxia and hypoxia.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left"/>
<th colspan="2" valign="bottom" align="center">Apoptotic percentage (&#x00025;)</th></tr>
<tr>
<th valign="bottom" align="left"/>
<th colspan="2" valign="bottom" align="left">
<hr/></th></tr>
<tr>
<th valign="bottom" align="left">Groups</th>
<th valign="bottom" align="center">Normoxia</th>
<th valign="bottom" align="center">Hypoxia</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Control</td>
<td valign="top" align="left">0.60&#x000B1;0.10</td>
<td valign="top" align="left">2.90&#x000B1;0.20<xref rid="tfn18-mmr-10-02-1108" ref-type="table-fn">a</xref></td></tr>
<tr>
<td valign="top" align="left">pE-Smac</td>
<td valign="top" align="left">0.67&#x000B1;0.15</td>
<td valign="top" align="left">2.53&#x000B1;0.47<xref rid="tfn17-mmr-10-02-1108" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">pH/E-Smac</td>
<td valign="top" align="left">0.73&#x000B1;0.06</td>
<td valign="top" align="left">5.07&#x000B1;0.15<xref rid="tfn18-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn16-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">2 Gy</td>
<td valign="top" align="left">2.87&#x000B1;0.15<xref rid="tfn16-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="left">7.27&#x000B1;0.25<xref rid="tfn18-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn16-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">pE-Smac+2 Gy</td>
<td valign="top" align="left">4.50&#x000B1;0.30<xref rid="tfn15-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="left">8.27&#x000B1;0.15<xref rid="tfn18-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn16-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">pH/E-Smac+2 Gy</td>
<td valign="top" align="left">4.80&#x000B1;0.30<xref rid="tfn15-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="left">17.8&#x000B1;0.83<xref rid="tfn17-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn16-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr></tbody></table>
<table-wrap-foot><fn id="tfn14-mmr-10-02-1108">
<p>Data are presented as the mean &#x000B1; standard deviation, n=3.</p></fn><fn id="tfn15-mmr-10-02-1108">
<label>d</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn16-mmr-10-02-1108">
<label>c</label>
<p>P&lt;0.01 versus control group;</p></fn><fn id="tfn17-mmr-10-02-1108">
<label>b</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn18-mmr-10-02-1108">
<label>a</label>
<p>P&lt;0.001 versus normoxia.</p></fn><fn id="tfn19-mmr-10-02-1108">
<p>pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tV-mmr-10-02-1108" position="float">
<label>Table V</label>
<caption>
<p>Relative mRNA expression of Cyt <italic>c</italic>, caspase-9 and -3 in A549 cells under normoxia and hypoxia.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left"/>
<th colspan="4" valign="bottom" align="center">Relative mRNA expression</th></tr>
<tr>
<th valign="bottom" align="left"/>
<th colspan="4" valign="bottom" align="left">
<hr/></th></tr>
<tr>
<th valign="bottom" align="left">Groups</th>
<th valign="bottom" align="center">Smac</th>
<th valign="bottom" align="center">Cyt <italic>c</italic></th>
<th valign="bottom" align="center">Caspase-9</th>
<th valign="bottom" align="center">Caspase-3</th></tr></thead>
<tbody>
<tr>
<td colspan="5" valign="top" align="left">Normoxia</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Control</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">1</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac</td>
<td valign="top" align="center">1.09&#x000B1;0.05</td>
<td valign="top" align="center">1.06&#x000B1;0.05</td>
<td valign="top" align="center">1.03&#x000B1;0.03</td>
<td valign="top" align="center">1.09&#x000B1;0.06</td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac</td>
<td valign="top" align="center">1.09&#x000B1;0.06</td>
<td valign="top" align="center">1.08&#x000B1;0.06</td>
<td valign="top" align="center">1.06&#x000B1;0.06</td>
<td valign="top" align="center">1.05&#x000B1;0.04</td></tr>
<tr>
<td valign="top" align="left">&#x02003;2 Gy</td>
<td valign="top" align="center">4.42&#x000B1;0.51<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">1.73&#x000B1;0.32</td>
<td valign="top" align="center">5.89&#x000B1;0.19<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">5.72&#x000B1;0.29<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac+2 Gy</td>
<td valign="top" align="center">20.51&#x000B1;1.67<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">7.22&#x000B1;0.27<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">5.76&#x000B1;0.10<xref rid="tfn22-mmr-10-02-1108" ref-type="table-fn">b</xref></td>
<td valign="top" align="center">32.03&#x000B1;2.49<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac+2 Gy</td>
<td valign="top" align="center">20.23&#x000B1;0.75<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">7.41&#x000B1;0.42<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">6.91&#x000B1;0.28<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">32.08&#x000B1;3.60<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td></tr>
<tr>
<td colspan="5" valign="top" align="left">Hypoxia</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Control</td>
<td valign="top" align="center">2.82&#x000B1;0.13<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">1.23&#x000B1;0.10</td>
<td valign="top" align="center">2.34&#x000B1;0.06<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">3.06&#x000B1;0.16<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac</td>
<td valign="top" align="center">2.75&#x000B1;0.09<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">1.27&#x000B1;0.15</td>
<td valign="top" align="center">2.56&#x000B1;0.07<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">3.18&#x000B1;0.17<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac</td>
<td valign="top" align="center">6.34&#x000B1;0.26<xref rid="tfn22-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">1.20&#x000B1;0.04<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">6.04&#x000B1;0.13<xref rid="tfn22-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">3.12&#x000B1;0.04<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;2 Gy</td>
<td valign="top" align="center">9.75&#x000B1;0.72<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">2.83&#x000B1;0.34<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">12.73&#x000B1;1.21<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">11.14&#x000B1;0.23<xref rid="tfn22-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pE-Smac+2 Gy</td>
<td valign="top" align="center">10.66&#x000B1;0.68<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">7.64&#x000B1;0.43<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">13.12&#x000B1;1.53<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">41.82&#x000B1;1.57<xref rid="tfn22-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td></tr>
<tr>
<td valign="top" align="left">&#x02003;pH/E-Smac+2 Gy</td>
<td valign="top" align="center">39.71&#x000B1;2.69<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">16.8&#x000B1;0.80<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td>
<td valign="top" align="center">19.56&#x000B1;0.99<xref rid="tfn21-mmr-10-02-1108" ref-type="table-fn">a</xref>,<xref rid="tfn23-mmr-10-02-1108" ref-type="table-fn">c</xref></td>
<td valign="top" align="center">59.09&#x000B1;1.59<xref rid="tfn22-mmr-10-02-1108" ref-type="table-fn">b</xref>,<xref rid="tfn24-mmr-10-02-1108" ref-type="table-fn">d</xref></td></tr></tbody></table>
<table-wrap-foot><fn id="tfn20-mmr-10-02-1108">
<p>Data are presented as the mean &#x000B1; standard deviation, n=3.</p></fn><fn id="tfn21-mmr-10-02-1108">
<label>a</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn22-mmr-10-02-1108">
<label>b</label>
<p>P&lt;0.01 versus control group;</p></fn><fn id="tfn23-mmr-10-02-1108">
<label>c</label>
<p>P&lt;0.05 and</p></fn><fn id="tfn24-mmr-10-02-1108">
<label>d</label>
<p>P&lt;0.001 versus normoxia.</p></fn><fn id="tfn25-mmr-10-02-1108">
<p>Smac, second mitochondria-derived activator of caspases; Cyt <italic>c</italic>, cytochrome <italic>c</italic>; pE-Smac, pcDNA3.1-Egr1-Smac; pH/E-Smac, pcDNA3.1-HRE/Egr1-Smac.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
